Clinical trial TELLOMAK
TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multicohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma
| Cancers | |
|---|---|
| Organ | Lymphoma |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Innate Pharma SA |
| EudraCT Identifier | 2018-003969-33 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03902184 |
| Inclusion criteria | Age >18> 2 lines Prior treatment with MogamulizumabRelapsed/refractory stage KIR3DL2 expressionEcog 0-2 |
| Last update |